title: Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
authors.affiliation: The David Geffen School of Medicine at UCLA, Los Angeles, Calif., USA. glassock @ cox.net
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Glassock
mesh_terms: D000419:Albuminuria / Q000175:diagnosis*; D015415:Biomarkers; D002986:Clinical Trials as Topic / Q000592:standards*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000628:therapy; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy / Q000652:urine*; D008137:Longitudinal Studies; D008297:Male; D012107:Research Design; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers